Shell Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.27M | Sell |
2,779
-4,478
| -62% | -$1.82M | 0.13% | 182 |
|
|
2025
Q2 | $2.37M | Buy |
7,257
+1,602
| +28% | +$443K | 0.08% | 235 |
|
|
2025
Q1 | $1.53M | Sell |
5,655
-337
| -6% | -$86.6K | 0.07% | 231 |
|
|
2024
Q4 | $1.41M | Sell |
5,992
-205
| -3% | -$53.9K | 0.06% | 253 |
|
|
2024
Q3 | $1.7M | Buy |
+6,197
| New | +$1.61M | 0.08% | 221 |
|
|
2024
Q1 | $722K | Sell |
2,973
-828
| -22% | -$138K | 0.03% | 370 |
|
|
2023
Q4 | $728K | Sell |
3,801
-1,031
| -21% | -$176K | 0.03% | 389 |
|
|
2023
Q3 | $856K | Sell |
4,832
-77
| -2% | -$14.7K | 0.04% | 389 |
|
|
2023
Q2 | $932K | Sell |
4,909
-99
| -2% | -$19.6K | 0.04% | 385 |
|
|
2023
Q1 | $1M | Buy |
5,008
+492
| +11% | +$103K | 0.04% | 366 |
|
|
2022
Q4 | $1.07M | Sell |
4,516
-347
| -7% | -$74K | 0.05% | 352 |
|
|
2022
Q3 | $973K | Sell |
4,863
-1,898
| -28% | -$362K | 0.04% | 372 |
|
|
2022
Q2 | $986K | Buy |
6,761
+639
| +10% | +$90.7K | 0.03% | 427 |
|
|
2022
Q1 | $1M | Buy |
6,122
+314
| +5% | +$47.8K | 0.02% | 493 |
|
|
2021
Q4 | $985K | Buy |
5,808
+2,053
| +55% | +$382K | 0.02% | 565 |
|
|
2021
Q3 | $709K | Sell |
3,755
-172
| -4% | -$32.3K | 0.02% | 683 |
|
|
2021
Q2 | $666K | Buy |
3,927
+960
| +32% | +$141K | 0.01% | 769 |
|
|
2021
Q1 | $419K | Buy |
2,967
+153
| +5% | +$23K | 0.01% | 923 |
|
|
2020
Q4 | $366K | Sell |
2,814
-59
| -2% | -$7.88K | 0.01% | 924 |
|
|
2020
Q3 | $418K | Sell |
2,873
-316
| -10% | -$44.9K | 0.01% | 759 |
|
|
2020
Q2 | $472K | Sell |
3,189
-1,315
| -29% | -$177K | 0.01% | 682 |
|
|
2020
Q1 | $490K | Buy |
4,504
+100
| +2% | +$11.5K | 0.01% | 676 |
|
|
2019
Q4 | $507K | Sell |
4,404
-1,288
| -23% | -$128K | 0.01% | 880 |
|
|
2019
Q3 | $458K | Hold |
5,692
| – | – | 0.01% | 946 |
|
|
2019
Q2 | $413K | Buy |
5,692
+1,730
| +44% | +$133K | 0.01% | 990 |
|
|
2019
Q1 | $370K | Hold |
3,962
| – | – | 0.01% | 1010 |
|
|
2018
Q4 | $289K | Sell |
3,962
-1,954
| -33% | -$150K | 0.01% | 988 |
|
|
2018
Q3 | $518K | Sell |
5,916
-3,946
| -40% | -$397K | 0.01% | 948 |
|
|
2018
Q2 | $971K | Sell |
9,862
-2,060
| -17% | -$204K | 0.02% | 695 |
|
|
2018
Q1 | $1.42M | Sell |
11,922
-11,849
| -50% | -$1.53M | 0.03% | 503 |
|
|
2017
Q4 | $3.02M | Buy |
+23,771
| New | +$2.99M | 0.06% | 320 |
|
|
2016
Q4 | – | Sell |
-3,345
| Closed | -$227K | – | 1057 |
|
|
2016
Q3 | $227K | Hold |
3,345
| – | – | ﹤0.01% | 965 |
|
|
2016
Q2 | $186K | Sell |
3,345
-368
| -10% | -$23.2K | ﹤0.01% | 836 |
|
|
2016
Q1 | $233K | Buy |
3,713
+201
| +6% | +$13.4K | 0.01% | 810 |
|
|
2015
Q4 | $331K | Buy |
+3,512
| New | +$326K | 0.01% | 771 |
|
|
2015
Q3 | – | Sell |
-6,049
| Closed | -$725K | – | 834 |
|
|
2015
Q2 | $725K | Buy |
+6,049
| New | +$723K | 0.01% | 683 |
|
|
2014
Q1 | – | Sell |
-6,300
| Closed | -$405K | – | 841 |
|
|
2013
Q4 | $405K | Sell |
6,300
-7,000
| -53% | -$418K | 0.01% | 771 |
|
|
2013
Q3 | $851K | Hold |
13,300
| – | – | 0.02% | 724 |
|
|
2013
Q2 | $412K | Buy |
+13,300
| New | +$354K | 0.01% | 749 |
|
Other funds holding ALNY
Shell Asset Management's ALNY Position: Q3 2025 in Review
Shell Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 62% in Q3 2025, selling an estimated $1.82M and leaving 2,779 shares worth $1.27M. The position accounts for 0.13% of the portfolio, ranked #182.
Shell Asset Management first reported a position in ALNY in Q2 2013 and has held it in 39 quarters since. The position peaked at $3.02M in Q4 2017. 822 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.
- Shell Asset Management held 2,779 shares of Alnylam Pharmaceuticals worth $1.27M as of Q3 2025.
- Shell Asset Management sold 4,478 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $1.82M.
- Alnylam Pharmaceuticals made up 0.13% of Shell Asset Management's portfolio in Q3 2025, its #182 holding.
- Shell Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 39 quarters since.
- Shell Asset Management's Alnylam Pharmaceuticals position peaked at $3.02M in Q4 2017.
- 822 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.
Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.